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Ventral prostate development occurs by branching morphogenesis and is an androgen-dependent process modulated by
growth factors. Many growth factors have been implicated in branching morphogenesis including activins (dimers of bA and
bB subunits); activin A inhibited branching of lung and kidney in vitro. Our aim was to examine the role of activins on
rostatic development in vitro and their localization in vivo. Organ culture of day 0 rat ventral prostates for 6 days with
ctivin A (1/2 testosterone) inhibited prostatic branching and growth without increasing apoptosis. The activin-binding
rotein follistatin increased branching in vitro in the absence (but not presence) of testosterone, suggesting endogenous
ctivins may reduce prostatic branching morphogenesis. In vivo, inhibin a subunit was not expressed until puberty,
herefore inhibins (dimers of a and b subunits) are not involved in prostatic development. Activin bA was immunolocalized
o developing prostatic epithelium and mesenchymal aggregates at ductal tips. Activin bB immunoreactivity was weak
during development, but was upregulated in prostatic epithelium during puberty. Activin receptors were expressed
throughout the prostatic epithelium. Follistatin mRNA and protein were expressed throughout the prostatic epithelium.
The in vitro evidence that activin and follistatin have opposing effects on ductal branching suggests a role for activin as a
negative regulator of prostatic ductal branching morphogenesis. © 2001 Academic Press
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iINTRODUCTION
Branching morphogenesis of the prostate is an androgen-
sensitive process elicited via epithelial–mesenchymal inter-
actions modulated by growth factors (Cunha et al., 1995).
The rat prostate begins to develop late in gestation, when
the urogenital sinus mesenchyme induces formation of
epithelial buds from the urogenital sinus epithelium (Sug-
imura et al., 1986; Hayashi et al., 1991; Timms et al., 1994).
hese buds elongate and form solid epithelial cords, which
row toward the ventral mesenchymal pad (Timms et al.,
995; Thomson and Cunha, 1999). The solid prostatic buds
longate and branch under the influence of androgens and
ubdivide the ventral mesenchymal pad into caps of mes-
nchyme that surround individual epithelial bud tips. Con-
urrent with ductal branching, epithelial differentiation
egins in the more proximal ductal regions near the urethra
1 To whom correspondence should be addressed. Fax: (613) 9594
e7115. E-mail: Gail.Risbridger@med.monash.edu.au.
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All rights of reproduction in any form reserved.nd then extends distally. This process involves differentia-
ion of the solid epithelial cords into canalized ducts lined
y columnar epithelial cells underlaid by a discontinuous
ayer of basal cells (Hayward et al., 1996a). The surrounding
esenchyme differentiates into smooth muscle or fibro-
lastic cells (Hayward et al., 1996b). Ductal branching
orphogenesis and epithelial differentiation continue in
he rat until about 40–50 days when branching ceases and
analization is completed in the ductal tips (Sugimura et
l., 1986). Rising androgens at puberty initiate secretory
unction of the epithelium (Lopes et al., 1996).
The actions of androgens during prostatic development
re elicited via reciprocal epithelial–mesenchymal interac-
ions modulated by growth factors. For example, fibroblast
rowth factor (FGF)-7 and FGF-10 are implicated in
ndrogen-induced ductal growth and branching morphogen-
sis of the prostate (Sugimura et al., 1996; Thomson and
unha, 1999). These factors are also implicated in branch-
ng morphogenesis of the lung (Peters et al., 1994; Bellusci
t al., 1997). Many other factors also regulate the complex
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146 Cancilla et al.interactions during branching morphogenesis including
members of the transforming growth factor (TGF)b super-
amily, such as bone morphogenetic proteins (BMPs) and
ctivins. Activin A reduces branching morphogenesis in the
eveloping pancreas, salivary gland, and kidney in vitro
Ritvos et al., 1995). In the prostate, the process of branch-
ng morphogenesis is similar to other organs, although the
evelopmental process is androgen-dependent.
Activins are members of the TGFb superfamily, and
consist of disulphide-linked homo- and heterodimers of bA
and bB subunits (forming activins A, AB, and B). Inhibins
onsist of a bA or bB subunit linked to an inhibin a subunit
forming inhibins A and B). Activins and inhibins were
riginally isolated as gonadal proteins that can regulate
ituitary follicle-stimulating hormone secretion (Burger et
l., 1988; De Jong, 1988). Inhibins are endocrine hormones
roduced by the gonads, which inhibit follicle-stimulating
ormone secretion. Activins are growth and differentiation
actors with diverse roles in development (Welt and Crow-
ey, 1998). Activin A acts as a mesoderm inducer in Xeno-
us embryos (Thomsen et al., 1990; van den Eijnden-Van
aaij et al., 1990; Smith et al., 1990; Albano et al., 1990),
and activins A and B can induce digit formation in chick
embryos (Merino et al., 1999). Mammary-derived activin bB
subunit is required for normal mammary gland develop-
ment (Robinson and Hennighausen, 1997). Mammary tis-
sue recombinants with bB subunit-deficient mice show that
stromal activin bB subunit is essential for normal ductal
longation and alveolar morphogenesis (Robinson and Hen-
ighausen, 1997).
The actions of activins cannot be considered in isolation
ue to the activity of the activin-binding and -neutralizing
lycoproteins, follistatins (FS). Several isoforms occur, re-
ulting from differential mRNA splicing to generate the
roteins FS-288 and FS-315. FS-288 binds to heparin and is
ound on the cell surface and in extracellular matrix,
hereas FS-315 is secreted from cells and does not bind to
eparin (Sugino et al., 1993). Both forms of follistatin bind
ctivins and block their biological activity (Sugino et al.,
993). Activins, inhibins, and follistatin are expressed in
he human and rodent prostate (Risbridger et al., 1996;
homas et al., 1998; van Schaik et al., 2000). Activin bA
subunit is present in basal and secretory epithelial cells, and
activin bB subunit is predominantly in basal epithelial cells
of the adult human prostate (Thomas et al., 1997, 1998;
Ying et al., 1997); this expression is regulated by testoster-
one (Risbridger et al., 1997). The localization of activin
subunits during prostatic development is not known.
Based on previous studies showing that activin reduced
ductal branching of pancreas, salivary gland, and kidney
(Ritvos et al., 1995), we examined the effects of exogenous
activin and follistatin on prostatic development in vitro and
found that activin can regulate branching morphogenesis.
We then examined the spatio-temporal expression of ac-
tivin bA and bB subunits and follistatin during prostatic
evelopment to determine whether the pattern of expres- p
Copyright © 2001 by Academic Press. All rightion was consistent with a role for activin in prostatic
evelopment in vivo.
METHODS
Animals
Intact male Sprague–Dawley outbred rats from days 0 to 20 and
day 90 postpartum were killed. Ventral prostate lobes were micro-
dissected from newborn rats and processed for organ culture,
reverse transcriptase–polymerase chain reaction (RT-PCR), or im-
munohistochemistry. All animals were obtained from Central
Animal Services, Monash University. Procedures and animal care
were administered according to the requirements, and with the
approval of the Standing Committee of Ethics in Animal Experi-
mentation, Monash University. Two sets of six ventral prostate
lobes at each age examined (days 0, 5, 10, 15, 20, and 90) were used
for RNA isolation as previously described (Cancilla et al., 2000).
For immunohistochemistry, tissues were fixed in Bouins, pro-
cessed to paraffin, and 3-mm serial sections were cut.
Organ Culture
Organ culture was carried out as previously described (Lipschutz
et al., 1997; Jarred et al., 2000). Briefly, microdissected day-0
ventral prostates were cultured on Millicell CM filters (Millipore
Corp., Bedford, MA) floating on 500 ml of nutrient media at 37°C in
a humidified 5% CO2 incubator. A basal medium of DMEM/Ham’s
-12, 1:1 (vol/vol), supplemented with insulin (10 mg/ml) and
ransferrin (10 mg/ml) was utilized in all experimental groups, and
edia was replenished every 48 h. In order to reduce variability of
rowth between animals, one ventral prostate lobe from each gland
as used for experimental treatment and the other for control
ultures. Different doses of activin A (10–100 ng/ml) and follistatin
0.1–3.5 mg/ml) were tested; the optimal dose of activin A was 40
ng/ml, and follistatin was 3.5 mg/ml. Human recombinant activin
was a gift from Biotechnology Australia Pty. Ltd. Purified bovine
ollistatin, containing FS-288 and FS-315 isoforms, was kindly
rovided by Prof. D. de Kretser (Monash Institute of Reproduction
nd Development, Australia). Explants were incubated with activin
or follistatin in the presence or absence of 10 nM testosterone.
he organs were harvested after 6 days of culture. Explants were
hotographed, fixed in Bouins for 2 h at room temperature, then
rocessed to paraffin. At least four pairs of explants were subjected
o each condition and dose tested.
RT-PCR
Reverse transcription (RT) and polymerase chain reaction (PCR)
were performed sequentially in the same reaction tube by using a
GeneAmp RNA PCR kit (Perkin Elmer, Foster City, CA) as
previously described (Cancilla et al., 2000). PCR was performed for
35 cycles, with 30 s at 95°C for denaturation, 30 s at 55°C for
annealing, and 1 min at 72°C for extension. Controls for RT-PCR
omitted the reverse transcriptase (non-RT control) or RNA (H2O
ontrol), which were replaced with water. To confirm the presence
f RNA in all samples, primers for cytoskeletal b actin were used
Tokunaga et al., 1986). The forward primer was 59-
TGGGCCGCCCTAGGCACCA and the reverse primer was 59-
TCTTTGATGTCACGCACGATTTC and generated an RT-PCR
roduct of 540 bp. To detect inhibin a, primers used were identical
s of reproduction in any form reserved.
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147Activin A and Follistatin in Prostate Branchingto those described previously for rat inhibin a subunit (Sonoyama
et al., 2000) and generated an RT-PCR product of 656 bp.
Antibodies
Activin bA subunit was detected by using clone E4 (raised against
mino acids 82–114 of human activin bA subunit) at 2–4 mg/ml.
Activin bB subunit was detected using biotinylated clone C5 (raised
gainst amino acids 82–114 of human activin bB subunit) at 7
mg/ml; this antibody cross-reacts with bA subunit (Illingworth et
al., 1996). FS-315 was detected by using clone H10 (raised against a
C terminus peptide of human FS-315; CDEDQDYSFPISSILEW;
Saito et al., 1991) at 5 mg/ml. This antibody has been used
previously for immunohistochemistry (McPherson et al., 1999). E4,
C5, and H10 were kind gifts from Prof. N. P. Groome (Oxford
Brookes University). Antibodies against three activin receptors,
anti-activin RIA, anti-activin RIIA, and anti-activin RIIB antibodies
(R & D Systems, Minneapolis, MN), were used at 10 mg/ml.
Smooth muscle cells were detected by using monoclonal anti-
smooth muscle a-actin (Sigma, St. Louis, MO) at 7 mg/ml, or with
FITC-labeled anti-smooth muscle a-actin (Sigma) at 19 mg/ml.
Undifferentiated prostatic epithelial cells and differentiated basal
cells were detected by using anti-high molecular weight cytokera-
tins (Dako, Carpinteria, CA) at 1 mg/ml. Proliferating cells were
etected by using monoclonal anti-Ki-67 antibodies (NCL-Ki67-
M11; Novocastra Laboratories) at a dilution of 1:50.
Control sections were incubated with concentration-matched
ouse IgG or goat IgG (Dako) instead of primary antibodies.
pecificity of E4, C5, and H10 was confirmed by preabsorption of
ntibodies with 103 excess immunizing peptide for 3 h prior to
ncubation on tissue sections.
Immunohistochemistry
Immunohistochemistry was performed as previously described
(Cancilla et al., 2000) with the following modifications. Sections
(except those stained for activin receptors) were subjected to
microwave antigen retrieval in 10 mM citrate buffer (pH 6.0). In
addition, sections stained for high molecular weight cytokeratins
were incubated with 0.01% trypsin, 0.2% CaCl2 for 10 min. All
ections were then treated with 3% (vol/vol) H2O2 in methanol for
30 min, and blocked with CAS block (Zymed Laboratories, San
Francisco, CA).
Sections were then incubated with primary antibodies or con-
trols overnight at 4°C (for bA, FS-315, high molecular weight
cytokeratins and Ki-67) or 2 h at room temperature (for smooth
muscle a-actin and activin receptors). Antibodies (except for ac-
ivin receptors) were detected by incubation with peroxidase-
abeled polymer (Dako Envision System; Dako) for 30 min then
olor-reacted with 3,39-diaminobenzidine tetrahydrochloride
DAB). To detect bB subunit, sections were incubated with an
xcess of E4 antibody (10 mg/ml) for 3 h at room temperature prior
to incubation with biotinylated-C5 antibody overnight at 4°C. The
biotinylated-C5 was then detected by incubation with Vectastain
Elite ABC kit (Vector) for 1 h and color-reacted with DAB. To
detect the activin receptors (ActRIA, ActRIIA, and ActRIIB), sec-
tions were incubated with biotinylated rabbit anti-goat IgG
(Zymed) at 5 mg/ml for 30 min at room temperature and then
incubated with Vectastain Elite ABC kit (Vector) for 45 min and
color-reacted with DAB. All reactions were stopped in water, and
sections were counterstained with Mayer’s haematoxylin, dehy-
drated, cleared, and mounted.
Copyright © 2001 by Academic Press. All rightFor double-labeling of high molecular weight cytokeratins and
smooth muscle a-actin, sections were stained for high molecular
eight cytokeratins as described above. Before counterstaining,
ections were incubated with double stain enhancer (Zymed) for 10
in. After rinsing with PBS, sections were incubated with CAS
Zymed) followed by anti-smooth muscle a-actin for 1 h and
etected with peroxidase-labeled polymer (Dako Envision System).
ections were color-reacted with Vector peroxidase substrate kit
Vector VIP; Vector), counterstained with Mayer’s haematoxylin,
ehydrated, cleared, and mounted.
For double labeling of activin and smooth muscle a-actin,
sections were stained for activin bA subunit as described above.
ections were then blocked with CAS (Zymed) and incubated with
ITC-labeled anti-smooth muscle a-actin for 1 h, rinsed, then
coverslipped with fluorescent mounting medium.
For detection of Ki-67, all sections from the different experimen-
tal groups were immunostained together and the color reaction was
developed for the same length of time to ensure that any differences
in staining intensity were due to the experimental conditions
instead of differences between immunohistochemistry experi-
ments.
Detection of Apoptosis
Apoptosis was analyzed by ApopTag In Situ Apoptosis Detection
Kit (Intergen, Purchase, NY). Briefly, sections were dewaxed, incu-
bated in Equilibration Buffer (Intergen), then treated with TdT
enzyme in Reaction Buffer (Intergen) for 1 h at 37°C. Sections were
washed in Stop/Wash Buffer (Intergen) for 30 min at 37°C, treated
with 3% (vol/vol) H2O2 in PBS for 15 min, and blocked with CAS
block (Zymed). Apoptotic cells were detected by anti-digoxigenin
conjugate (Intergen) for 30 min at room temperature and color-
reacted with DAB. The reactions were stopped in water, and
sections were counterstained with Mayer’s haematoxylin, dehy-
drated, cleared, and mounted.
In Situ Hybridization
In situ hybridization was performed by using digoxigenin-
labeled follistatin riboprobes as previously described (Thomas et
al., 1997). This follistatin riboprobe detects both mRNA variants of
follistatin. Briefly, sections were dewaxed, rehydrated, digested
with 2–5 mg/ml proteinase K (Boehringer Mannheim, Castle Hill,
NSW, Australia) for 30 min at 37°C, stopped with glycine, and
treated with acetic anhydride. Sections were then prehybridized at
42°C for 30 min. Riboprobes (at 200 ng/ml) were hybridized onto
sections overnight at 42°C. Riboprobes were detected with alkaline
phosphatase-conjugated goat anti-digoxigenin (Boehringer Mann-
heim) and visualized with 5-bromo-chloro-indolyl phosphate/nitro
blue tetrazolium (BCIP/NBT; Boehringer Mannheim).
RESULTS
Prostatic Development in Vivo
The development of the rat ventral prostate was divided
into three overlapping stages: branching morphogenesis,
which occurred between days 0 and 6 postpartum; differen-
tiation, which occurred in a proximal to distal manner and
was most pronounced between days 6 and 10; and matura-
tion of secretory function, which began with the onset of
puberty and was well established in the adult.
s of reproduction in any form reserved.
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148 Cancilla et al.From days 0–4, the prostate consisted of solid epithelial
buds (positive for high molecular weight cytokeratins) that
grew out from the urogenital sinus toward the ventral
mesenchymal pad. These buds branched into and subdi-
vided the mesenchymal pad into caps of aggregated mesen-
chyme surrounding the tip of each epithelial bud (Figs.
1A–1D). This mesenchymal cap was maintained at all
epithelial bud tips until epithelial branching ceased. The
solid epithelial cords differentiated to form a polarized
epithelium characterized by cuboidal or columnar epithe-
lial cells and basal cells, concurrent with lumen formation
(canalization) (Figs. 1E–1H). The developing stroma differ-
entiated into thin smooth muscle sheaths surrounding the
epithelial ducts and a fibroblastic stroma containing invad-
ing blood vessels (Figs. 1C and 1D). Between days 4 and 10,
the solid epithelial cords of distal bud tips continued to
branch. Progressive epithelial differentiation and ductal
canalization occurred as the prostatic ducts continued to
grow (Figs. 1E–1H). Between days 10 and 15, extensive
maturation of the differentiated prostatic ducts occurred
(Figs. 1G–1J) and secretory activity began.
Prostatic Development in Organ Culture
Development and differentiation in vitro were similar to
that observed in vivo. The prostatic explants grew over the
6 days of organ culture in the presence of 10 nM testoster-
one from a small explant at day 0 with two main ducts per
side already having two to three branch points (Fig. 2A) to a
much larger organ rudiment with extensive branching of
the prostatic epithelial ducts (Fig. 2B). In section, immuno-
histochemistry for high molecular weight cytokeratins and
smooth muscle a actin revealed a similar architecture to
that observed in vivo, with canalized ducts surrounded by a
smooth muscle sheath at the center of the explant, and
solid epithelial cords (high molecular weight cytokeratin
positive) at the periphery of the explant (Fig. 2C). A cap of
condensed mesenchyme surrounded the tips of the branch-
ing solid epithelial cords (Fig. 2D) similar to that observed
in vivo (see above). Cellular proliferation was also examined
by using Ki-67, and many positive cells were observed in
the ductal tips and mesenchyme (Fig. 2E). Activin A can
induce apoptosis of adult prostatic epithelial cells (Wang et
al., 1996; McPherson et al., 1999), and therefore we exam-
ined the level of apoptosis in control explants cultured with
testosterone alone. We found that, although the explant
was growing, some apoptotic cells were detected (Fig. 2F).
Effect of Activin A on Prostatic Organ Cultures
Administration of exogenous activin A inhibited ductal
branching morphogenesis (Fig. 2G). In the presence of
testosterone, overall explant growth was reduced (Figs. 2G
and 2H), with fewer branches than the pair-matched control
(Figs. 2B and 2C). In activin-treated explants, the epithelial
tips and surrounding mesenchymal cap were expanded (Fig.
2I) compared to testosterone-treated explants (Fig. 2D). e
Copyright © 2001 by Academic Press. All righttromal differentiation was also inhibited in the activin-
reated explants compared to controls. Smooth muscle
ifferentiation, which extended to near the periphery of the
xplant in control cultures (Fig. 2C), was only observed in
he center of the activin-treated explants (Fig. 2H). An
FIG. 1. Rat prostatic development in vivo. Immunolocalization of
high molecular weight cytokeratins (brown staining) and a smooth
uscle actin (purple staining) in developing rat ventral prostate
obes at days 0 (A, B), 4 (C, D), 8 (E, F), and 15 (G, H). (A) At day 0,
he solid epithelial buds (high molecular weight cytokeratin posi-
ive) have grown into the ventral mesenchymal pad and begun to
ranch. (B) The mesenchymal pad has been subdivided by these
uds to form caps of aggregated mesenchyme (arrowheads) sur-
ounding the bud tips. (C–F) As branching continues, the buds of
pithelial cells differentiate from cells that are high molecular
eight cytokeratin positive (brown staining) to cuboidal or colum-
ar epithelial cells (high molecular weight cytokeratin negative)
verlying basal cells (G, H), and the mesenchyme differentiates
nto thin smooth muscle sheaths (purple staining) and fibroblastic
troma. Lumen formation (canalization) begins at day 4 (C) and
xtensive maturation is seen by day 15 (G, H). Bar in (A), 500 mm in
A), (C), (E), and (G); 50 mm in (B), (D), (F), and (H).xpanded zone of undifferentiated mesenchyme was also
s of reproduction in any form reserved.
(arrowheads) is shown at higher magnification. (E) Many prolifer- (
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Copyright © 2001 by Academic Press. All rightobserved at the periphery of activin-treated explants (Figs.
2H and 2I) compared to controls (Figs. 2C and 2D). A
reduction in proliferation was observed following activin
treatment as determined by staining for Ki-67 (Fig. 2J). The
alterations in the extent of branching and maturation of the
ducts and stroma in the presence of activin A were not due
to increased apoptosis in any segment or compartment of
activin-treated explants (Fig. 2K) compared to controls (Fig.
2F). A similar effect of activin was observed in the absence
of testosterone, where the limited branching was even
further reduced by activin A, causing stunted branches and
an expanded undifferentiated mesenchymal zone (data not
shown).
Effect of Follistatin on Prostatic Organ Cultures
Explants treated with follistatin in the presence of testos-
terone were no different than control explants treated with
testosterone alone (Figs. 3A and 3B). Prostatic explants
cultured with 10 nM testosterone were growing under
maximal growth conditions, thus a further increase in
growth may not be observed. We therefore examined pros-
tatic explants in the absence of testosterone. In control
explants grown in the absence of testosterone, limited
branching was observed (Fig. 3C). In section, these explants
had a poorly differentiated stroma with few smooth muscle
cells (Fig. 3D). The solid epithelial cords had differentiated
in the absence of testosterone to form high molecular
weight cytokeratin-positive basal cells and high molecular
weight cytokeratin-negative epithelial cells but without
canalization of the ducts (Figs. 3D and 3E). Limited prolif-
eration and apoptosis were observed in these explants (Figs.
3F and 3G). Under these conditions, addition of exogenous
follistatin increased growth and branching of the prostatic
explant (Fig. 3H) beyond that observed in untreated controls
(Fig. 3C). The increase in growth with follistatin alone (Fig.
3H) was less than that observed with androgens (Figs. 3A
and 3B). The stroma of follistatin-treated explants was more
differentiated than controls with smooth muscle surround-
ating cells (Ki-67 positive, brown staining) are observed in the
epithelium and mesenchyme. (F) Some apoptosis was detected in
mesenchyme and epithelium (arrows) following organ culture with
10 nM testosterone alone. (G) Pair-matched prostatic explant from
the same animal as in (B) following 6 days of culture with 10 nM
testosterone and 40 ng/ml activin A. Activin A inhibited branching
morphogenesis compared to controls. (H) Section through the
explant in (G) showing stunted epithelial buds (high molecular
weight cytokeratin-positive), with an expanded cap of mesen-
chyme (arrowheads), shown at higher magnification in (I). (J) Ki-67
staining revealed a marked decrease in proliferation following
activin A treatment compared to control explants (E). (K) No
increase in apoptosis was detected (arrows) following organ culture
with activin A compared to control (F). Bar in (A), 500 mm in (A–C),FIG. 2. Prostatic development in vitro in the presence of andro-
gens, and the effect of activin A treatment. (A) Day-0 rat ventral
prostate with two main ducts that have branched into the ventral
mesenchymal pad. (B) Extensive growth and branching is seen in
the prostatic explant following 6 days of culture with 10 nM
testosterone. (C) Section through the explant, with high molecular
weight cytokeratin-positive solid epithelial buds (brown staining)
at the periphery and canalized ducts with a smooth muscle sheath
(purple) at the center. (D) A solid epithelial bud (high molecular
weight cytokeratin-positive) with surrounding mesenchymal capG), and (H). Bar in (D), 50 mm in (D–F) and (I–K).
s of reproduction in any form reserved.
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Copyright © 2001 by Academic Press. All righting epithelial ducts further toward the periphery of the
explant (Figs. 3I and 3J). The epithelial ducts in follistatin-
treated explants were similar to untreated controls, with
high molecular weight cytokeratin-positive basal cells and
high molecular weight cytokeratin-negative epithelial cells
(Fig. 3J). Even though the epithelium in the proximal
portion of the explant consisted of columnar epithelial cells
with basal cells, these ducts did not have a lumen. Cellular
proliferation was increased in FS-treated explants (Fig. 3K)
compared to controls (Fig. 3F) reflecting the increased
growth and branching in these explants. Again, no changes
in the level of apoptosis were observed in cultures with the
addition of follistatin compared to controls (Figs. 3G and
3L).
Collectively, the organ culture data showed that activin
A and follistatin modulated prostatic ductal branching,
development, and growth in vitro. We therefore determined
whether other members of the activin and inhibin family
were involved during prostatic development by examining
their expression and localization during prostatic develop-
ment and differentiation.
Expression of Inhibin Subunit during Prostatic
Development
RT-PCR with b actin primers showed that mRNA was
resent in all prostate samples from day 0 to adult (Fig. 4A).
similar to the control testosterone-treated explant. Follistatin had
no effect under maximal growth conditions (10 nM T). (C) Prostatic
explant following 6 days of organ culture in the absence of
testosterone (2T); limited ductal branching is seen. (D) Section
through the explant showing few branches with some smooth
muscle differentiation (purple staining). (E) At higher magnifica-
tion, the solid epithelial cords have differentiated into high mo-
lecular weight cytokeratin-negative epithelial cells and high mo-
lecular weight cytokeratin-positive basal cells (brown staining), but
these ducts have not canalized in the absence of testosterone. Few
proliferating cells can be seen in these explants (F), and apoptosis in
these organs is limited (G). (H) Pair-matched prostatic explant from
the same animal as in (C) following 6 days of culture with 3.5
mg/ml follistatin in the absence of testosterone (2T 1 FS). Follista-
tin increased growth and branching compared to control (C) but not
as much as testosterone-treated explants (A, B). (I) Section through
the explant in (H) showing epithelial ducts and differentiating
smooth muscle stroma. (J) At higher magnification, follistatin
treatment in the absence of testosterone resulted in ducts with
epithelia that have differentiated into basal cells with overlying
cuboidal/columnar epithelial cells. Again, these ducts have not
undergone canalization. In addition, the mesenchymal cap is
reduced and the differentiating stroma reaches closer to the tip of
the differentiating duct than that of controls or testosterone-treated
explants. (K) An increase in proliferating cells (Ki-67) is seen in
follistatin-treated explants compared to controls, reflecting the
increased growth and branching in these cultures. (L) No difference
is observed in the levels of apoptosis with follistatin treatment
compared to controls. Bar in (A), 500 mm in (A–D), (H), and (I). BarFIG. 3. Prostatic development in vitro, and the effect of follistatin
reatment. (A) Prostatic explant following 6 days of culture with 10
M testosterone (T), showing extensive growth and branching. (B)
air-matched prostatic explant following treatment with 10 nMin (E), 50 mm in (E–G) and (J–L).
s of reproduction in any form reserved.
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151Activin A and Follistatin in Prostate BranchingRT-PCR showed that inhibin a subunit mRNA was not
xpressed in the developing prostate (day 0 and 5) but some
xpression was detected once the prostate had begun to
ature at day 10 (Fig. 4B). Expression was then maintained
n the pubertal prostate at day 15, day 20, and in the adult
rostate at day 90 (Fig. 4B). This indicates that inhibin
ynthesis does not occur until the prostate begins maturing
nto a secretory organ. No RT-PCR products were observed
n any of the non-RT or H2O controls.
Inhibin a subunit mRNA was not expressed in the
developing rat prostate, thus inhibin proteins are not in-
volved in prostatic development. We therefore examined
the localization of activin bA and bB subunit proteins and
heir binding protein, follistatin, during rat prostatic devel-
pment.
Immunolocalization of Activin bA Subunit
Immunolocalization of bA subunit was observed in the rat
prostate throughout development during branching mor-
phogenesis, differentiation, and maturation of secretory
function (Fig. 5). Distinct immunoreactivity for bA subunit
was localized to the cap of undifferentiated mesenchyme
surrounding the epithelial bud tips (Figs. 5A and 5B).
Immunoreactivity for bA was maintained in the mesenchy-
al cap at all epithelial bud tips (Figs. 5B–5E) until branch-
ng morphogenesis ceased. No bA subunit protein was
bserved in the undifferentiated mesenchyme at the periph-
ry of the developing organ (Fig. 5A) or in the differentiated
troma that surrounded the ductal epithelium (Figs. 5B–
D). Weak immunostaining for bA subunit was present in
FIG. 4. Expression of inhibin a subunit in the developing rat
rostate. (A) RT-PCR products for the positive control cytoskeletal
b actin (540 bp) were detected in all samples at all ages. (B) RT-PCR
products of 656 bp for inhibin a subunit mRNA were not detected
ntil day 10 postpartum. Inhibin a subunit mRNA expression was
hen maintained in the maturing and adult prostate. For each
ample, “1” and “2” indicate the presence or absence of RT and5he water control is labeled H2O.
Copyright © 2001 by Academic Press. All righthe solid epithelial buds at day 0, and was maintained in the
pithelial cords as they elongated and branched (Figs. 5A–
FIG. 5. Localization of activin bA subunit in the developing rat
rostate. Immunoreactivity for bA subunit was localized to the mes-
enchymal cap (arrowheads) surrounding the epithelial bud tips at days
2 (A), 4 (B–D), and 8 (E). Weak immunostaining for bA subunit was
seen in the epithelium from days 2–10 (A–F) and was upregulated in
the epithelium at day 15 (G–F). bA subunit was not localized to the
ifferentiating smooth muscle stroma (asterisks) in the developing
nd maturing prostate. This was shown by double staining the
ections for bA with a smooth muscle actin (B–D and G–I). Preabsorp-
tion of the antibody with the immunizing peptide showed no immu-
nostaining (J, K). Bar, 50 mm for (A) and (E–K), and 100 mm for (B–D).E). As the prostate ceased developing and began matura-
s of reproduction in any form reserved.
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152 Cancilla et al.tion during puberty, immunostaining for bA subunit was
bserved in epithelial cells of canalized ducts at day 10 (Fig.
F), and was present throughout the epithelium at day 15
Fig. 5G). No staining was observed in the smooth muscle
urrounding the differentiating ducts (Figs. 5H and 5I). This
attern was maintained in the adult rat (data not shown),
onsistent with activin A as a secretory product of the
rostatic epithelium (Risbridger et al., 1996). No staining
as observed when the antibodies were preabsorbed with
he corresponding activin bA subunit immunizing peptide
(Figs. 5J and 5K).
Immunolocalization of Activin bB Subunit
Immunostaining for bB subunit during prostatic develop-
ment was different from that of activin bA. In contrast to
the focal localization of bA protein in the mesenchymal cap,
bB staining was only observed in some cells of the mesen-
chyme and fibroblastic stroma (Figs. 6A–6D). Weak immu-
nostaining was observed in the solid epithelial cords and
canalized ducts (Figs. 6A–6C) during development. In the
maturing prostate, strong immunostaining was observed in
columnar epithelial cells of the more mature canalized
ducts at day 15 (Fig. 6D). No bB subunit immunostaining
was present in the differentiated smooth muscle stroma
(Fig. 6D). Activin bB subunit was present throughout the
pithelium at day 20 (data not shown) and this pattern of
ocalization was maintained in the epithelium of the adult
at (data not shown).
Expression and Immunolocalization of Follistatin
In situ hybridization was performed to detect follistatin
RNA by using a riboprobe that detects both splice vari-
nts of follistatin mRNA (FS-288 and FS-315). Follistatin
RNA was expressed throughout the prostatic epithelium
uring development and differentiation (Figs. 6E–6G), and
as maintained in the epithelium of pubertal (Fig. 6H) and
dult animals. In differentiating prostates (days 10–15),
ollistatin mRNA was reduced in the maturing epithelium
oward the center of the gland (Fig. 6H). No staining was
bserved in sense controls at any age (Figs. 6I–6L). Using a
at-reactive antibody to FS-315, this follistatin protein was
ocalized to prostatic epithelium during development and
ifferentiation (Figs. 6M–6O). Immunolocalization was
aintained in the epithelium of pubertal (Fig. 6P) and adult
nimals consistent with the mRNA expression of follistatin
n prostatic epithelium.
Immunolocalization of Activin Receptors
Activin type I and type II receptors were expressed during
prostatic development (Fig. 7). ActRIA was localized
throughout the prostatic epithelium and to the developing
stromal compartment (Fig. 7A) with staining in the stroma
and developing blood vessels. ActRIIA was strongly local-
ized throughout the prostatic epithelium (Fig. 7B). ActRIIB
Copyright © 2001 by Academic Press. All rightFig. 7C) was also localized predominantly to the developing
rostatic epithelium. No immunostaining was observed in
he goat IgG negative control (Fig. 7D).
DISCUSSION
Activins are growth and differentiation factors with di-
verse roles in development. This study provides evidence
for a functional role of activin A and follistatin in prostatic
development. The specific pattern of prostatic expression of
activin bA and bB subunits is consistent with a role for
activin A rather than other activin or inhibin ligands in
prostatic development. In other systems, the bioactivity of
activins may be controlled by follistatin, or regulated by the
interplay between activins and inhibins (Hsueh et al., 1987;
McLachlan et al., 1987; Risbridger and Cancilla, 2000).
lthough we detected the inhibin a subunit in the pubertal
prostate, inhibin a subunit was not expressed in the devel-
ping prostate. Instead, we detected follistatin mRNA and
rotein in vivo, and showed that follistatin had an opposing
ction to activin A in vitro. The predominantly epithelial
ocalization of activin receptors in the developing prostate
nd co-localization of epithelial activin with follistatin
uggests that the precise localization of endogenous activin
within the tip mesenchyme is required for paracrine
ontrol of branching morphogenesis by activin A. These
ata show that the interplay between activin A and follista-
in is important in regulating prostatic branching morpho-
enesis (summarized in Fig. 8).
Our study and that of Ritvos et al. (1995) provide func-
ional evidence of a role for activin A in branching morpho-
enesis. The inhibition of branch formation and epithelial
longation observed in the prostate gland was similar to
hat observed in the kidney, pancreas, and salivary gland
Ritvos et al., 1995). However, the dose of activin A required
o achieve inhibition of branching varied between the
ifferent organs examined. A lower dose of activin A (40
g/ml) was required in the prostate (present study) and
ancreas (Ritvos et al., 1995), but higher doses of activin A
ere required for disruption of kidney and salivary gland
evelopment. This differential response could be due to the
isparate distributions of endogenous activin and follistatin
n these structurally distinct branching organs. In the
idney, follistatin expression was localized to the periph-
ral mesenchyme (Ritvos et al., 1995) in contrast to the
epithelial expression we observed in the prostate.
Activin B is involved in branching morphogenesis of
other organs. The activin bB subunit is essential for normal
ductal elongation and alveolar morphogenesis of the
estrogen-dependent mammary gland (Robinson and Hen-
nighausen, 1997). Specific roles for activins A and B have
not been fully explored due to a lack of purified activin B
ligands, but recent in vivo studies show that some of the
unctions of activin A can be replaced by activin B (Brown et
l., 2000). Activin bA knockout mice were rescued fromsome of the major defects caused by the absence of endog-
s of reproduction in any form reserved.
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153Activin A and Follistatin in Prostate Branchingenous bA subunit by replacing the missing activin bA gene
with activin bB. However, activin bB could not replace
activin bA in developing testes or in ovarian function
Brown et al., 2000).
Previous studies have shown that activin A induces
poptosis of adult prostatic epithelial cells in vitro and in
rostatic tumor cell lines (Wang et al., 1996; McPherson et
FIG. 6. Localization of activin bB subunit, and follistatin expressi
ivity for bB subunit was observed in epithelium during developme
epithelial cells of the more mature canalized ducts (D). Immunos
esenchyme and fibroblastic stroma throughout development (A–
showed that follistatin mRNA was expressed throughout the pro
(E–H). At day 15, follistatin mRNA was reduced in the maturing ep
with follistatin sense [FS (s)] riboprobes (I–L). Follistatin protein
differentiation and maturation (M–P), identical to the pattern of mRl., 1999). In our study, we found that exogenous activin did
Copyright © 2001 by Academic Press. All rightot enhance cell death in the developing prostate at any
ose examined; no increase in apoptosis was observed in the
pithelium or mesenchyme of prostates exposed to exog-
nous activin A in vitro. Similarly, apoptosis was not
bserved in epithelia of developing kidney, pancreas, and
alivary gland exposed to activin A in vitro (Ritvos et al.,
995). Excess circulating activins in the inhibin a knockout
nd localization in the developing rat prostate. Weak immunoreac-
–C). At day 15, strong immunostaining was observed in columnar
ng for activin bB subunit was also observed in some cells of the
n situ hybridization with follistatin antisense [FS (as)] riboprobes
epithelium during development, differentiation and maturation
lium toward the center of the gland (H). No staining was observed
315) was localized to prostatic epithelium during development,
expression. Bar 5 50 mm for (A–D) and (M–P), and 500 mm for (E–L).on a
nt (A
taini
D). I
static
ithe
(FS-mouse do not induce apoptosis in the developing gastric
s of reproduction in any form reserved.
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154 Cancilla et al.epithelium but instead the excess activins block differen-
tiation of specific cell types in the gastric mucosa (Li et al.,
1998). The lack of apoptosis in response to exogenous
activin A may be due to neutralization by endogenous
follistatin (McPherson et al., 1999). Alternatively, the de-
eloping prostate may not be competent to undergo apopto-
is upon exposure to exogenous activin A. In contrast to an
poptotic role for activin A, we did observe a decrease in
roliferation in response to activin A treatment, and a
orresponding increase in proliferation in response to fol-
istatin treatment. A similar response to activin A was
bserved in other cell types where activin A inhibited DNA
ynthesis (McCarthy and Bicknell, 1993; Yasuda et al.,
993; Carcamo et al., 1994).
Although activins are TGFb family members, the re-
orted actions of TGFb on branching morphogenesis are not
the same as those we have described for activin A. Exog-
enous TGFb was shown to inhibit ductal branch formation,
ut did not inhibit elongation of existing ducts, suggesting
hat these two processes have distinct controlling mecha-
isms. This effect of TGFb was observed in intact organs
uch as prostate, kidney, and lung (Cunha et al., 1995;
itvos et al., 1995; Chinoy et al., 1998) as well as in
ultures of kidney epithelial cells grown in a mesenchyme-
ree matrix (Santos and Nigam, 1993; Sakurai and Nigam,
997). Conversely, exogenous activin A inhibited branch
ormation and elongation in the developing prostate such
hat the ductal tips did not bifurcate and elongate but
FIG. 7. Localization of activin type I and type II receptors in the
developing rat prostate. (A) Immunostaining for actRIA is localized
throughout the prostatic epithelium at day 2, and to the developing
stroma and developing blood vessels. (B) ActRIIA is strongly
immunolocalized throughout the prostatic epithelium. (C) ActRIIB
is also localized predominantly to the developing prostatic epithe-
lium. (D) No immunostaining is seen in the goat IgG-negative
control. Bar, 50 mm for (A–D).ontinued to expand as a solid cluster of cells (Fig. 8). The r
Copyright © 2001 by Academic Press. All rightredominantly epithelial localization of activin receptors in
he developing prostate suggests that exogenous activin A
an act in a paracrine manner on the developing epithelium.
utocrine activity of activin A in prostatic epithelium may
e inhibited by the presence of endogenous follistatin.
In addition to epithelial localization, activin bA subunit
as localized to the remnants of the ventral mesenchymal
ad at the epithelial bud tips but not the surrounding
esenchyme or developing stroma. This pattern of activin
bA expression is different from that of TGFb, which was
localized throughout the mesenchyme of the developing
mouse and human prostate (Timme et al., 1995; Raghow et
al., 1999). The localization of activin bA in the developing
prostate was also different from that of another member of
the TGFb family, BMP-4 (Lamm et al., 2001), which was
localized to the prostatic mesenchyme between epithelial
branch points. Culture with exogenous BMP-4 reduced bud
formation from the fetal urogenital sinus (Lamm et al.,
2001), which was different from the effects of exogenous
activin A on the newborn prostate (present study).
Interestingly, localization of activin bA subunit in the
developing rat prostate is more similar to that described for
BMP-7 in the developing kidney. BMP-7 was localized to
the condensed nephrogenic mesenchyme at the ureteric
bud tips, and was also localized to the ureteric epithelium
(Godin et al., 1998). Treatment of kidney explants with
xogenous BMP-7 in vitro inhibited branching morphogen-
sis of the ureteric bud (Piscione et al., 1997; Godin et al.,
998) and resulted in an expanded zone of mesenchyme
Dudley et al., 1999). This is similar to the effects of
xogenous activin A on prostatic explants observed in the
resent study. Activin A may play a role in maintaining the
ip mesenchyme in the prostate, as exogenous activin A
ncreased the size of the mesenchyme surrounding the
rostatic bud tips (Fig. 8).
In the kidney, BMP-7 was found to interact with FGF-2 to
romote survival and maintain competence of metanephric
esenchyme (Dudley et al., 1999). These authors suggested
hat signaling between the two mesenchymal populations
f the kidney (nephrogenic mesenchyme and surrounding
esenchyme) maintained the mesenchymal cap at branch
ips during kidney development. An interaction between
ctivin and FGF has been shown in the brain, where the
europrotective effects of FGF-2 during stroke were due to
he induction of activin A (Tretter et al., 2000). A similar
echanism may be acting in the prostate between FGFs
nd activin A, where the promotion of branching morpho-
enesis by FGFs in the prostate (Sugimura et al., 1996;
homson and Cunha, 1999) may be modulated by activin
. Thus, a balance between maintenance and growth of
uctal tip mesenchyme and rate of ductal branching mor-
hogenesis is essential for proper organogenesis (Fig. 8).
We found follistatin expression and localization in pros-
atic epithelium throughout development. In addition to
eutralizing epithelial activin during development, our in
itro data suggest that follistatin may be modulating the
ate of branching morphogenesis of the prostate. A similar
s of reproduction in any form reserved.
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155Activin A and Follistatin in Prostate Branchingeffect was observed in the pancreas (Miralles et al., 1998),
where the exocrine tissue of pancreatic rudiments does not
develop in the absence of mesenchyme in vitro but could be
induced by exogenous follistatin. In our study, follistatin
was able to increase prostatic development and branching
morphogenesis but was unable to mimic the full effects of
testosterone on prostatic development in vitro. Our data
suggest that a balance between activin and follistatin is
important for prostatic branching morphogenesis, but that
other factors or hormones are needed for proper ductal
canalization and maturation. In addition to the regulation
of activin activity, follistatin can also bind to members of
the BMP family, such as BMP-4 and BMP-7 (Fainsod et al.,
1997; Iemura et al., 1998), although with much lower
affinity than for activin. The localization of BMP-7 in the
prostate is not known. BMP-4 localization in the developing
FIG. 8. Schematic diagram of the roles of activin A and follistati
several stages: (A) epithelial bud stage, with a surrounding cap of co
the developing epithelium; (B) cleft formation, where the epitheliu
mesenchyme expands to cover this extended structure; (C) cleft st
matrix production, and the expanded mesenchymal zone is now
extension, where the newly formed branches grow and extend out fr
branch formation and epithelial extension. As the epithelial buds b
epithelium. A balance between endogenous activin and follistat
destabilization of the cleft, thus inhibiting branching of the epitheli
stromal maturation. As proliferation is not inhibited, the epithelial
with a reduction in the size of the mesenchymal cap, an increase i
an increase in maturing stroma surrounding the differentiating epprostate (Lamm et al., 2001) is different from that of activin
Copyright © 2001 by Academic Press. All rightbA, but since both BMP-4 and activin A reduced prostatic
growth, it is possible that the increase in growth observed
with exogenous follistatin may include inhibition of endog-
enous BMP ligands in prostatic explants.
Activin bA and follistatin knockout mice die just before
birth, therefore the prostatic effects of an absence of activin
A or follistatin cannot be determined in these mice (Matzuk
et al., 1995a,c). Activin bB (Vassalli et al., 1994) and activin
receptor type II (actRII) knockout mice (Matzuk et al.,
1995b) survive after birth and have some defects. Although
these mice are fertile, their prostates have not been exam-
ined. Transgenic mice expressing a truncated actRII, which
acts as a dominant negative activin receptor have been
generated. This truncated receptor blocks signaling by ac-
tivin and other TGF family members (Maeshima et al.,
2000). These mice survived after birth and were apparently
rostatic branching morphogenesis. Branching can be divided into
sed mesenchyme at the tip and differentiating stroma surrounding
egins to grow outward from the tip and a cleft is formed, and the
ation, where the newly formed cleft is stabilized by extracellular
between the newly formed epithelial branches; and (D) branch
he cleft. Stromal development and maturation are concurrent with
h and grow, the stroma differentiates and surrounds the maturing
required to maintain this process. An excess of activin causes
nd a continual expansion of the mesenchymal cap, thus inhibiting
continue to expand. An excess of follistatin has the opposite effect,
ft stabilization, and more branching. Excess follistatin also causes
al ducts.n in p
nden
m b
abiliz
split
om t
ranc
in is
um, a
buds
n clenormal; however, analysis of their kidneys showed that
s of reproduction in any form reserved.
156 Cancilla et al.these mice have more glomeruli than wild-type littermate
controls. Glomeruli (and their associated nephron) develop
at the tips of the branched ureteric bud. Therefore, in-
creased branching morphogenesis presumably occurred
when activin signaling was reduced in the kidney (Mae-
shima et al., 2000). We saw a similar effect when follistatin
was added to prostatic organ cultures; activin signaling was
attenuated, and an increased number of branches was
observed.
In conclusion, the present results indicate that activin bA
subunit and follistatin, but not activin bB subunit or inhibin
a, are important during prostatic development. The in vitro
data on activin A and follistatin, together with the discrete
localization of activin bA to the mesenchymal cap of ductal
tips and localization of activin receptors to prostatic epithe-
lium, suggest important roles for activin during branching
morphogenesis of the prostate. Our data indicate that
activin A acts as a negative regulator of branching morpho-
genesis, either directly through activin receptors or indi-
rectly through other growth factors and/or inhibitors.
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